ClinicalTrials.gg
CompletedNCT01485770Updated Jul 6, 2021Results posted

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

A Phase 2 interventional study of ADX-N05 and Placebo in Narcolepsy, sponsored by Jazz Pharmaceuticals. Completed at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-06.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.

Enrollment
13th of 15
33 · median 120
Started
2011
the only one that year
Phase 2
3 of 18
none open now
Registered
4th of 18
by date

Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2011, is one of 3 in phase 2, and was the 4th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Narcolepsy by Jazz Pharmaceuticals, or all of them as a file.
02

Study summary

This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.

03

Conditions studied

  • Narcolepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of narcolepsy
  • Good general health
  • Willing and able to comply with the study design and schedule and other requirements

Exclusion criteria

Exclusion Criteria:

  • If female, pregnant or lactating
  • Customary bedtime later than midnight
  • History of significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history
  • Any other medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness
  • History of significant cardiovascular disease
  • >34
  • Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day
  • History of alcohol or drug abuse within the past two years
  • Nicotine dependence that has an affect on sleep
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Placebo, Then ADX-N05

    Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).

    Drug: ADX-N05 · Drug: Placebo

  • Placebo comparator
    ADX-N05, Then Placebo

    Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).

    Drug: ADX-N05 · Drug: Placebo

Interventions

  • 150 mg once a day for seven days followed by 300 mg once a day for seven days

  • DrugPlacebo

    Placebo to match ADX-N05 once a day for 2 consecutive weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With ADX-N05 vs. Two Weeks of Treatment With Placebo

    The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The change from baseline in the mean sleep latency from the MWT was the average of sleep latency from the four trials of the MWT.

    Time frame: Baseline up to 2 weeks post-dose.

Secondary outcomes

  1. Change From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 1 and 3

    The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

    Time frame: Baseline up to Week 3 post-dose.

  2. Change From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 2 and 4

    The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

    Time frame: Baseline up to Week 4 post-dose.

  3. Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 1 and 3

    The CGI-C scale was completed at Week 1 through 4 visits. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of participants experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the two weeks of each of the treatment periods. The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

    Time frame: Week 1 and Week 3 post-dose.

  4. Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 2 and 4

    The CGI-C scale was completed at Week 1 through 4 visits. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of participants experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the two weeks of each of the treatment periods. The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

    Time frame: Week 2 and Week 4 post-dose.

07

Results

Posted Jul 6, 2021

Participant flow

First Intervention (2 Weeks)
Participant flow — First Intervention (2 Weeks)
MilestonePlacebo, Then ADX-N05ADX-N05, Then Placebo
Started1716
Completed1716
Not completed00
Second Intervention (2 Weeks)
Participant flow — Second Intervention (2 Weeks)
MilestonePlacebo, Then ADX-N05ADX-N05, Then Placebo
Started1716
Completed1716
Not completed00

Outcome measures

PrimaryChange From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With ADX-N05 vs. Two Weeks of Treatment With Placebo

The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The change from baseline in the mean sleep latency from the MWT was the average of sleep latency from the four trials of the MWT.

Time frame:
Baseline up to 2 weeks post-dose.
Reported as:
Mean · minutes
Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With ADX-N05 vs. Two Weeks of Treatment With Placebo
minutesADX-N05 300 mgPlacebo
Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With ADX-N05 vs. Two Weeks of Treatment With Placebo12.7 ± 10.640.9 ± 6.02
SecondaryChange From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 1 and 3

The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

Time frame:
Baseline up to Week 3 post-dose.
Reported as:
Mean · score on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 1 and 3
score on a scaleADX-N05 150 mgPlacebo
Change From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 1 and 3-5.3 ± 5.20-1.2 ± 4.09
SecondaryChange From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 2 and 4

The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

Time frame:
Baseline up to Week 4 post-dose.
Reported as:
Mean · score on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 2 and 4
score on a scaleADX-N05 300 mgPlacebo
Change From Baseline in Epworth Sleepiness Scale (ESS) Score During Weeks 2 and 4-6.7 ± 6.15-2.4 ± 3.82
SecondaryNumber of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 1 and 3

The CGI-C scale was completed at Week 1 through 4 visits. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of participants experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the two weeks of each of the treatment periods. The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

Time frame:
Week 1 and Week 3 post-dose.
Reported as:
Count of participants · Participants
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 1 and 3
ParticipantsADX-N05 150 mgPlacebo
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 1 and 3299
SecondaryNumber of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 2 and 4

The CGI-C scale was completed at Week 1 through 4 visits. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of participants experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the two weeks of each of the treatment periods. The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

Time frame:
Week 2 and Week 4 post-dose.
Reported as:
Count of participants · Participants
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 2 and 4
ParticipantsADX-N05 300 mgPlacebo
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores During Weeks 2 and 42513

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADX-N050/33 (0%)0/33 (0%)20/33 (60.6%)
Placebo0/33 (0%)0/33 (0%)0/33 (0%)
Most frequent other events
Most frequent other events
EventADX-N05Placebo
NauseaGastrointestinal disorders4/330/33
HeadacheNervous system disorders3/330/33
Chest discomfortGeneral disorders3/330/33
Initial InsomniaNervous system disorders2/330/33
InsomniaNervous system disorders2/330/33
AnxietyPsychiatric disorders2/330/33
Decreased AppetiteMetabolism and nutrition disorders2/330/33
Muscle tightnessMusculoskeletal and connective tissue disorders2/330/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo, Then ADX-N05ADX-N05, Then PlaceboTotal
Mean31.71 ± 11.5642.81 ± 10.7237.1 ± 12.35
Sex: Female, Male
Sex: Female, Male(Participants)Placebo, Then ADX-N05ADX-N05, Then PlaceboTotal
Female9514
Male81119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo, Then ADX-N05ADX-N05, Then PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino171633
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo, Then ADX-N05ADX-N05, Then PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American5510
White121123
More than one race000
Unknown or Not Reported000
08

Study locations

10 sites
  • Pulmonary Associates
    Phoenix, Arizona 85006, United States
  • Clinical Research Group of St. Petersburg
    Saint Petersburg, Florida 33707, United States
  • Neurotrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Sleep Disorders Center of Georgia
    Atlanta, Georgia 30342, United States
  • SleepMed of Central Georgia
    Macon, Georgia 31201, United States
  • The Center for Sleep and Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Mercy St. Anne Sleep Disorders Center
    Toledo, Ohio 43623, United States
  • SleepMed of South Carolina
    Columbia, South Carolina 29201, United States
  • Future Search Trials of Neurology
    Austin, Texas 78731, United States
  • Sleep Medicine Associates of Texas
    Dallas, Texas 75231, United States
09

References and documents

Publications

  • Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, Khayrallah M, Lankford DA. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015 Sep;16(9):1102-8. doi: 10.1016/j.sleep.2015.05.013. Epub 2015 Jun 3. PubMed 26298786 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2021, 9 years 2 months after primary completion. A results delay was requested in Mar 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2011
First posted
Dec 6, 2011
Start
Dec 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Results delay requested
Mar 8, 2013
Results first posted
Jul 6, 2021
Last update
Jul 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01485770
Responsible party
Sponsor
First posted
Dec 6, 2011
Start date
Dec 2011
Primary completion
May 2012
Completion
May 2012
Results posted
Jul 6, 2021
Last update
Jul 6, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion